Urology · Clinical trials
Overactive Bladder Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About overactive bladder — and why its trials are hard
Overactive bladder (OAB) is a symptom syndrome of urinary urgency, usually with frequency and nocturia, with or without urgency urinary incontinence, absent infection or other pathology. It reflects detrusor overactivity and afferent signalling dysfunction. First-line pharmacotherapy is antimuscarinics that block detrusor M3 receptors, including oxybutynin, tolterodine, and solifenacin, effective but limited by dry mouth, constipation, and cognitive effects in older adults. The beta-3 adrenergic agonist class relaxes the detrusor during storage without antimuscarinic burden: mirabegron (Myrbetriq, 2012) and vibegron (Gemtesa, 2020) are the approved agents. For refractory disease, intradetrusor onabotulinumtoxinA (approved 2013) and neuromodulation are options. Pivotal trials share co-primary endpoints of change in mean daily micturitions and daily urgency (urge) urinary incontinence episodes measured on validated bladder diaries. Treatment is well established with multiple effective classes, so the field's challenges are tolerability, adherence, and personalisation rather than efficacy gaps. Combination antimuscarinic-plus-beta-3 therapy is used for inadequate monotherapy responders.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Solifenacin (Vesicare) | 2004 | Oral antimuscarinic (M3-selective) for OAB with urgency, frequency, urge incontinence | Phase 3 program (e.g., pooled pivotal trials, VESIcare NDA) | Change in mean micturitions/24h and incontinence episodes | Significant reductions in daily micturitions and urgency incontinence episodes vs placebo (specific effect sizes unverified) |
| Mirabegron (Myrbetriq) | 2012 | Oral beta-3 adrenergic agonist for OAB | SCORPIO (Phase 3, and pooled with ARIES/CAPRICORN) | Co-primary: change from baseline in mean number of micturitions/24h and mean number of incontinence episodes/24h | Statistically significant reductions vs placebo (~0.4-0.6 fewer micturitions/24h and ~0.4 fewer incontinence episodes/24h over placebo in pooled data) |
| Vibegron (Gemtesa) | 2020 | Oral beta-3 adrenergic agonist (75 mg) for OAB | EMPOWUR (Phase 3, 12 weeks) | Co-primary: change from baseline in average daily micturitions and daily urge urinary incontinence (UUI) episodes at week 12 | Significant vs placebo: roughly 0.5 fewer micturitions/day and ~0.5 fewer UUI episodes/day over placebo |
| OnabotulinumtoxinA (Botox) | 2013 | Intradetrusor injection for OAB inadequately managed by anticholinergics | Pivotal Phase 3 (Nitti et al.) | Change in daily urgency urinary incontinence episodes | Reduction of roughly 2.5-3 more UUI episodes/day than placebo at 12 weeks (approximate) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in overactive bladder development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Elocalcitol (vitamin D receptor agonist) — Phase 2b, randomized placebo-controlled study in women with OAB and idiopathic detrusor overactivity | Did not meet its efficacy objective for OAB; development for the indication was not advanced to registration. | Insufficient symptomatic benefit over placebo on bladder-storage endpoints; the vitamin D receptor mechanism did not translate into clinically meaningful OAB efficacy. |
Choosing the right endpoint
Primary endpoints that matter in overactive bladder trials
- Mean micturitions per 24 hours — Core co-primary; captures frequency, recorded on bladder diaries.
- Urgency (urge) urinary incontinence episodes per 24 hours — Co-primary in incontinent populations; the most patient-relevant leak measure.
- Urgency episodes per 24 hours — Reflects the defining symptom of OAB; secondary endpoint in most trials.
- Volume voided per micturition — Secondary measure of functional bladder capacity improvement.
- Health-related quality of life (e.g., OAB-q) — Validated patient-reported secondary endpoint supporting clinical relevance.
How iNGENū runs overactive bladder trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Overactive Bladder clinical trials — FAQs
How do beta-3 agonists differ from antimuscarinics?
What endpoints define OAB trial success?
What if pills do not work?
Ready to discuss your overactive bladder trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal